This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -4.35% and 40.10%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Gossamer Bio (GOSS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
What Makes Gossamer Bio (GOSS) a New Buy Stock
by Zacks Equity Research
Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Gossamer Bio (GOSS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 52% Upside in Gossamer Bio (GOSS): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in Gossamer Bio (GOSS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Gossamer Bio (GOSS) Could Rally 113%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Gossamer Bio (GOSS) points to an 113.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Gossamer Bio (GOSS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Gossamer Bio (GOSS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Are Options Traders Betting on a Big Move in Gossamer Bio (GOSS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Gossamer Bio (GOSS) stock based on the movements in the options market lately.
Gossamer Bio's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Gossamer Bio.
New Strong Buy Stocks for May 8th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Bet on Rising P/E Investing With These Top 5 Stocks
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Will Gossamer Bio Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Gossamer Bio
Why Gossamer Bio (GOSS) Stock Might be a Great Pick
by Zacks Equity Research
Gossamer Bio (GOSS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Implied Volatility Surging for Gossamer Bio (GOSS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Gossamer Bio (GOSS) stock based on the movements in the options market lately.